Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Tough CEA Rules for Cost-Based Method Products Targeting Imports: EFPIA Japan Vice Chair
February 7, 2019
- Japan, US, European Trade Groups Give Opinions on Govt’s CEA Proposal: Chuikyo
February 7, 2019
- Kymriah Up for MHLW Panel Review on Feb. 20 as Japan’s 1st CAR-T Therapy
February 6, 2019
- MHLW Informs of Outlines for New Package Insert Format to Be Introduced in April
February 6, 2019
- Key MHLW Panel Backs Iron Replacement Therapy Ferinject, No Vyvanse Review
February 1, 2019
- Faulty Wage Data Might Have Affected Drug Pricing as Labor Stats Used for Cost-Based Method
January 31, 2019
- Janssen’s Erleada Clears MHLW Panel Review, Now in Line for March Approval
January 31, 2019
- Pharmacies Fret Inventory Value Dip, Negative Margins due to Tax Hike-Linked Re-Pricing: Chuikyo Public Hearing
January 31, 2019
- MHLW Calls for Thorough Check on Drugs after Cyanide Blackmail
January 30, 2019
- PMDA Eyeing Staffer Increase of Around 150 over Next 5 Years, Official Suggests
January 29, 2019
- MSD to Tap MID-NET Database for Erelsa/Grazyna in 3rd Private Sector Use
January 29, 2019
- MHLW Revises Notifications on Electronic Data Submission as End of Grace Period Approaches
January 28, 2019
- Resistant Virus Found in Kids Administered Xofluza: NIID
January 28, 2019
- NITE, Genome Pharmaceuticals Institute Jointly Explore Rare Actinomycetes for MRSA
January 28, 2019
- “Detailed Discussions” Necessary for Use of Real World Data: HSC Panel
January 25, 2019
- MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
- Maviret, Ibrance, PD-1 Inhibitors under PMDA Risk Review
January 21, 2019
- MHLW to Give Enough Preparation Time for Local Govts before New PMD Law Takes Effect
January 21, 2019
- Iron Deficiency Med Ferinject Up for MHLW Panel Review on Jan. 31; No Vyvanse Discussion This Time
January 18, 2019
- MHLW Panels Find No Major Safety Concern for 14 Vaccines: July-October
January 17, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…